{
    "clinical_study": {
        "@rank": "47003", 
        "arm_group": [
            {
                "arm_group_label": "SG2000 - 15 \u00b5g/m2/day", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 1 - will commence at 15 \u00b5g/m2/day intravenous doses of SG2000 until  Maximum Tolerated Dose is determined."
            }, 
            {
                "arm_group_label": "SG2000 - 30 \u00b5g/m2/day", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 2 - will commence at 30 \u00b5g/m2/day  intravenous doses of SG2000 until  Maximum Tolerated Dose is determined."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the experimental drug, SG2000 is safe and\n      tolerable in the treatment of participants with advanced chronic lymphocytic leukemia and\n      acute myeloid leukemia whose standard treatment did not work, whose cancer came back or who\n      are not candidates for other types of standard therapy."
        }, 
        "brief_title": "Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "Chronic Lymphocytic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male or female greater than or equal to 18 years of age\n\n          -  have one of the following disease states: Acute Myeloid Leukemia (AML) (age <60\n             years) with relapsed/refractory disease; \u2022Chronic Lymphocytic Leukemia (CLL) with\n             relapsed disease following a fludarabine-based regimen or relapsed disease following\n             an alkylator-based regimen\n\n          -  are recovered from the acute adverse effects of prior therapies (excluding alopecia\n             and Grade \u22642 neuropathy).\n\n          -  have blast counts that can be controlled by the use of hydroxycarbamide (500 to 3000\n             mg daily).\n\n          -  have adequate hepatic function and renal function\n\n          -  have an estimated life expectancy of >3 months\n\n          -  female subject must have a negative serum pregnancy result within 7 days before the\n             start of the study; Both men and women must agree to use a medically acceptable form\n             of contraception throughout the treatment period and for 3 months after\n             discontinuation of treatment\n\n        Exclusion Criteria:\n\n          -  are eligible for any standard therapy known to be life prolonging or life saving\n\n          -  have diagnosis of AML French-American-British (FAB) classification (FAB) M3 (acute\n             promyelocytic leukemia (APL))\n\n          -  are receiving concurrent chemotherapy, radiotherapy, immunotherapy, biological or\n             hormonal treatment for cancer.\n\n          -  have undergone anticancer therapy including chemotherapy (except for hydroxycarbamide\n             at a maximum daily dose of 3000 mg), endocrine therapy, immunotherapy, or the use of\n             other investigational agents within 4 weeks before study entry.\n\n          -  prior radiation therapy with volume of bone marrow treated over 25%.\n\n          -  use of immunosuppressive therapy, including systemic steroids within 7 days before\n             the first dose of SG2000.\n\n          -  hyperleukocytosis (blast counts >30 000/mm3).\n\n          -  history of allogeneic stem cell or solid organ transplantation.\n\n          -  positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C\n             or have HIV-AIDS, or active hepatitis B or C.\n\n          -  history of other invasive malignancy within 3 years except for cervical carcinoma in\n             situ, nonmelanomatous carcinoma of the skin or ductal carcinoma in situ of the breast\n             that has been surgically cured.\n\n          -  have any coexisting medical condition that will substantially increase the risk\n             associated with the subject's participation in the study.\n\n          -  have psychiatric disorders or altered mental status precluding understanding of the\n             informed consent process and/or completion of necessary studies.\n\n          -  have persistent Grade 2 or greater toxicities from any cause (except alopecia or\n             peripheral neuropathy).\n\n          -  are pregnant or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034227", 
            "org_study_id": "CL-2000-II-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "SG2000 - 15 \u00b5g/m2/day", 
                "SG2000 - 30 \u00b5g/m2/day"
            ], 
            "description": "intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).", 
            "intervention_name": "SG2000", 
            "intervention_type": "Drug", 
            "other_name": "DNA minor groove binding agent"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "leukemia", 
        "lastchanged_date": "January 9, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "David Rizzieri, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University"
                }, 
                "investigator": {
                    "last_name": "David Rizzieri, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Robert Stuart, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }, 
                "investigator": {
                    "last_name": "Robert Stuart, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia", 
        "overall_contact": {
            "email": "john.barnes@ppdi.com", 
            "last_name": "John Barnes, Senior Global Project Manager", 
            "phone": "512-484-9502"
        }, 
        "overall_contact_backup": {
            "last_name": "Matthew Cramblett, AD, Hematology/", 
            "phone": "+44 1698 572928"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Maximum Tolerated Dose (MTD) will be determined based on the assessment of the dose-limiting toxicity (DLT) during the DLT period;  period is defined as the time from the first dose intravenous doses of SG2000 for 3 consecutive days every 21 days for 1 to 6 cycles until unacceptable toxicity, consent withdrawal, or another reason to discontinue therapy intervenes.", 
            "measure": "Maximum Tolerated Dose (MTD) of SG2000.", 
            "safety_issue": "Yes", 
            "time_frame": "From 1st dose of SG2000 given on days 1, 2 and 3, every 21-days,  for six 21-day cycles (approximately 16 weeks)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034227"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Any subject who receives at least 1 dose of SG2000 will be evaluated for safety.\nSubjects will be monitored for adverse events (AEs) and will undergo safety assessments including full physical examination, vital sign assessment, Eastern Cooperative Oncology Group (ECOG) performance status assessment, and laboratory testing.", 
                "measure": "safety profile", 
                "safety_issue": "No", 
                "time_frame": "day -1 to day- 21 for six 21-day cycles ."
            }, 
            {
                "description": "pharmacokinetic (PK) parameter, noncompartmental  analysis will be performed to estimate the plasma pharmacokinetic (PK) parameters of SG2000. Area under the concentration-time curve (AUC).", 
                "measure": "area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "day-1 of each 21-day cycle (cycles 1 and 3) at the following time points: predose, 15 minutes (middle of infusion), 30 minutes(end of infusion), and at 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 24 hours after the end of infusion."
            }, 
            {
                "description": "pharmacokinetic (PK) parameter -Cmax is the observed maximum plasma or serum concentration after administration", 
                "measure": "Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "day-1 of each 21-day cycle (cycles 1 and 3) at the following time points: predose, 15 minutes (middle of infusion), 30 minutes (end of infusion), and at 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 24 hours after the end of infusion."
            }, 
            {
                "description": "pharmacokinetic (PK) parameter - time to reach Cmax.", 
                "measure": "time to reach Cmax", 
                "safety_issue": "No", 
                "time_frame": "day-1 of each 21-day cycle (cycles 1 and 3) at the following time points: predose, 15 minutes (middle of infusion), 30 minutes (end of infusion), and at 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 24 hours after the end of infusion."
            }, 
            {
                "description": "pharmacokinetic parameter - terminal half life", 
                "measure": "terminal half life (T1/2),", 
                "safety_issue": "No", 
                "time_frame": "day-1 of each 21-day cycle (cycles 1 and 3) at the following time points: predose, 15 minutes (middle of infusion), 30 minutes (end of infusion), and at 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 24 hours after the end of infusion."
            }, 
            {
                "description": "predictors of Vascular Leak Syndrome (VLS)", 
                "measure": "hematology and serum chemistry", 
                "safety_issue": "No", 
                "time_frame": "baseline, days 1,2,3,4,8,15, and 21 for six 21-day cycles."
            }, 
            {
                "description": "predictors of Vascular Leak Syndrome (VLS)", 
                "measure": "Physical examination", 
                "safety_issue": "No", 
                "time_frame": "baseline, day-1 to day 21 for six 21-day cycles."
            }, 
            {
                "description": "predictors of Vascular Leak Syndrome (VLS)", 
                "measure": "Vital signs", 
                "safety_issue": "No", 
                "time_frame": "baseline, day-1 to day-21 for six 21-day cycles."
            }, 
            {
                "measure": "bone marrow aspirate", 
                "safety_issue": "No", 
                "time_frame": "day-1 (predose), and day 8 of Cycles 1 and 3 , and day 1 of Cycles 2 and 4"
            }, 
            {
                "description": "monitoring for Vascular Leak Syndrome (VLS)", 
                "measure": "pulse oximetry", 
                "safety_issue": "No", 
                "time_frame": "baseline, day-1 to day-21 for six 21-day cycles."
            }, 
            {
                "measure": "electrocardiogram", 
                "safety_issue": "No", 
                "time_frame": "days 1, 8, 15, 21, and at Day 22 after the last cycle or early termination."
            }, 
            {
                "measure": "bone marrow aspirate", 
                "safety_issue": "No", 
                "time_frame": "day-1 (predose), and day- 8 of each 21-day cycle (cycles 1 and 3) and day -1 of cycles 2 and 4"
            }
        ], 
        "source": "Spirogen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spirogen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}